Ascendis Pharma vs ICON

Ascendis Pharma (ASND), health care, and ICON (ICLR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Ascendis Pharma is worth $17.8B on the stock market and ICON $14.6B: Ascendis Pharma is valued at 22% more. Ascendis Pharma trades at 17.8 times earnings and ICON at 78.0; operating margins in their latest fiscal years were -18.9% and 5.37%. Over the past year Ascendis Pharma's share price has moved +25.1% and ICON's +18.9%.

Key facts

Ascendis Pharma market value
$17.8B
ICON market value
$14.6B
Ascendis Pharma P/E
17.8
ICON P/E
78.0
Ascendis Pharma revenue
$799MFY to 2025-12-31
ICON revenue
$8.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Ascendis Pharma vs ICON: every measure side by side
Measure Ascendis Pharma ICON
SectorHealth CareHealth Care
Country Denmark Ireland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$17.8Bhigher$14.6Blower
Revenue$799Mlower$8.3Bhigher
Earnings-$253Mlower$229.3Mhigher
Employees1,189lower40,250higher
Total assets$1.4Blower$16.3Bhigher
Valuation
P/E17.8lower78.0higher
P/S22.3higher1.8lower
P/B——
Dividend yield——
Profitability
Operating margin-18.9%lower5.37%higher
Balance sheet
Net assets-$180.7Mlower$9.2Bhigher
Total liabilities$1.6Blower$7.1Bhigher
Total debt$799.1Mlower$2.9Bhigher
Cash on hand$683.5Mhigher$647.3Mlower
Price change
Today-0.20%lower+1.89%higher
1 year+25.1%higher+18.9%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns ASND · Who owns ICLR

Further comparisons

Learn

Questions and answers

Which is bigger, Ascendis Pharma or ICON?

By market value, Ascendis Pharma is the larger: $17.8B against $14.6B for ICON. By revenue in its latest fiscal year, ICON is the larger: $8.3B against $799M for Ascendis Pharma.

Which has the higher P/E ratio?

ICON: 78.0, against 17.8 for Ascendis Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

ICON: 5.37%, against -18.9% for Ascendis Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

ICON: $2.9B, against $799.1M for Ascendis Pharma. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Ascendis Pharma and ICON?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Ascendis Pharma and 13 hold ICON.

Cite this page

Funkfolio, “Ascendis Pharma vs ICON”, data as of 18 November 2026. https://funkfolio.com/compare/asnd-vs-iclr

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.